ESR1 and breast cancer: Cholesterol-lowering medication administered to patients with estrogen receptor positive (ER+) breast cancer during endocrine therapy has shown improved therapeutic outcomes (related to disease-free survival, breast cancer-free interval and distant recurrence-free interval) compared with nonusers [62].